<DOC>
	<DOCNO>NCT01511731</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Reddy Cheminor Merck &amp; Co , pepcid 40 mg famotidine tablet fast condition .</brief_summary>
	<brief_title>Bioavailability Study Famotidine Tablets 40 mg Under Fasting Conditions</brief_title>
	<detailed_description>Detailed Description : The study conduct open-label , randomize , single-dose , 2-way crossover , relative bioavailability study perform 30 healthy adult male volunteer . A total 30 subject complete clinical phase study . Single oral 40 mg dos separate washout period 7 day .</detailed_description>
	<mesh_term>Famotidine</mesh_term>
	<criteria>History presence significant : â€¢ cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction famotidine histamine H2receptor antagonist ; Subjects abnormal diet ( whatever reason ) four week precede study . Subjects , completion study , would donate excess : 500 mL blood 14 day , 500 750 mL blood 14 day ( unless approve Principal Investigator ) , 1000 mL blood 90 day , 1250 mL blood 120 day , 1500 mL blood 180 day , 2000 mL blood 270 day , 2500 mL blood 1 year . Subjects participate another clinical trial within 28 day study start .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>famotidine</keyword>
	<keyword>Crossover</keyword>
</DOC>